Switching patients with AMD from ranibizumab or aflibercept to faricimab

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the real-life effectiveness of switching patients with age-related macular degeneration (AMD) from existing anti-VEGF treatments, ranibizumab or aflibercept, to a new treatment option, faricimab. Faricimab is a bi-specific monoclonal antibody that targets both VEGF-A and ANG2, potentially allowing for longer intervals between injections compared to previous therapies. The study will include patients who have been treated with anti-VEGF for over a year and have injection intervals of less than 12 weeks. The goal is to assess the benefits of this switch in a practical setting, reflecting everyday clinical practice.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female patient of legal age (≥18 years) with exudative AMD treated with IVT ranibizumab or aflibercept \> 1 year.
* Patient whose IVT injection interval is strictly less than 12 weeks.

Exclusion Criteria:

* Severe myopia (axial length \> 26 mm or sphere \< - 6 dioptres).

  * Presence of angioid striae.
  * Presence of moderate or more severe diabetic retinopathy.
  * History of diabetic macular edema.
  * History of uveitis.
  * Previous retinal vein occlusion (branch or central vein).
  * History of pseudovitelliform macular dystrophy.
  * Patient under guardianship or trusteeship
  * Pregnant or breast-feeding woman

Where it's running

• Ducloyer
  Nantes, Nantes, France Recruiting

Study contacts

• Principal investigator: Jean-Baptiste Ducloyer, M.D — Nantes University Hospital
• Study coordinator: Jean-Baptiste Ducloyer, M.D
• Email: jeanbaptiste.ducloyer@chu-nantes.fr
• Phone: 02 40 08 34 01

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Early imaging changes with faricimab versus biosimilar ranibizumab for diabetic retinal disease

  This trial will see if faricimab or a biosimilar ranibizumab causes different early OCT and OCTA imaging changes in adults with diabetic retinopathy or diabetic macular edema who need anti-VEGF injections.

  Recruiting Osijek University Hospital · Osijek · NCT07520045

• Personalized treat-and-extend faricimab regimen for treatment-naive polypoidal choroidal vasculopathy

  This tests whether a personalized treat-and-extend dosing schedule of faricimab (Vabysmo) helps people with newly diagnosed polypoidal choroidal vasculopathy keep or improve their vision.

  Recruiting Phase 3 Yeungnam University College of Medicine · Daegu, Namgu · NCT07461441

• Understanding Age-Related Macular Degeneration and Its Progression

  This study looks at how age-related macular degeneration develops and progresses by comparing people with the condition to healthy individuals, using non-invasive tests and personal feedback.

  Recruiting Center for Eye Research Australia · East Melbourne, Victoria · NCT04739319

• Switching from ranibizumab to aflibercept for eye conditions

  This study is testing if switching patients with certain eye conditions from one medication to another can help improve their vision.

  Recruiting Medical University of Vienna · Vienna · NCT02669953

• Blepharoptosis After Repeated Anti-VEGF Injections in One Eye

  This study tests whether repeated intravitreal anti-VEGF injections in one eye affect eyelid position compared with the untreated fellow eye.

  Recruiting Fatih Sultan Mehmet Training and Research Hospital · Istanbul · NCT07821450

• Faricimab for CNV in Presumed Ocular Histoplasmosis Syndrome

  This study tests whether Faricimab can safely and effectively treat choroidal neovascularization linked to presumed ocular histoplasmosis in adults over a 52-week period.

  Recruiting at 2 sites Phase 4 Cincinnati Eye Institute, Southwest Ohio · Cincinnati, Ohio and 1 other locations · NCT07695298

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.